Galenix Brings its Galenic Drugs to BIO 2007 in Boston

Galenix, a pharmaceutical R&D company founded in 1993, has pioneered the development of a number of drug delivery systems (DDS).

[ClickPress, Thu Apr 19 2007] Situated near the community of Saint-Jean d’Illac near Bordeaux, France, Galenix has developed three proprietary DDS for oral or parenteral use in slow, fast, or bimodal modified-release profiles: MICROGIX ®, MINEXTAB ®, and MINEXTAB ® FLOATING.

MICROGIX ® is a dispersed system that improves the bio-availability and/or solubility of chemical entities or biologicals. The active pharmaceutical ingredient is first dispersed in a water/oil or oil/water preparation. The preparation is then adsorbed in a powder that can be packed in sachets, stick packs, or used for manufacturing tablets, capsules, or parenteral dosage forms.

MINEXTAB ® is intended to reduce the tablet size thanks to a reduced excipient level (less than 15% of the formula). This DDS is designed for high-dosage forms (500 to 1000 mg) or lower-dosage forms for pediatric use. MINEXTAB ® FLOATING is intended for drugs with gastric absorption. It also reduces tablet size, but makes the tablet float above the food in the stomach. In this system, two excipients react with water and form CO2 bubbles that are captured inside the matrix to lift the tablet above the surface of food.

Galenix had also developed two trademarked powders, MUCOLYS ® FILM and MUCOLYS ® FLASH, for incorporation in spray-delivered medicines or in stick packs. MUCOLYS ® FILM forms a film once in contact with the mucous membrane inside the mouth. The film will remain for a maximum of five hours and release the drug through the mucous membrane. This allows a sustained release and avoids the first-pass effect. MUCOLYS ® FLASH is a powder in a spray. The powder dissolves in less than five seconds in the saliva under the tongue. This technology serves the purposes of immediate-release drugs that need to avoid the first-pass effect.

In addition to developing DDS for biotech and pharmaceutical companies, Galenix is involved in the whole pharmaceutical development process. Between the company’s three divisions, Galenix Innovations, Development, and Pharma, it provides sub-contracted pharmaceutical development services including characterization of the active pharmaceutical ingredient, formulation, analytical development, clinical batches production, stability studies, quality control, and regulatory submission (NDA, CTD). The company currently employs 74 people including highly qualified engineers, PhDs, post-doctorates, and technicians, and meets FDA and European GMP requirements. In 2006, Galenix’s turnover was 12.2 million EUR ($16.5 million USD).

For more information, please contact:

Galenix
Christine Adam-Perchec
Pharmacist – Business Development
Allée des Palanques
33127 SAINT JEAN D’ILLAC
France
Tel: +33 (0)5 56 68 83 00
Fax: +33 (0)5 56 68 83 01
E-mail: c.adam@galenix.fr
Web: www.galenix.fr

or

FRENCH TECHNOLOGY PRESS OFFICE
205 North Michigan Avenue, Suite 3740
Chicago, IL 60601
Fax: (312) 327-5261
E-mail: contact.ftpo@ubifrance.fr

Bookmark this release: Del.icio.us - Digg - Furl - Blinklist - Reddit